Policy

Providing health care for Olympic athletes can put a heavy burden on both the competitors and their doctors to deliver that care and to pay for such care in the long term.

The closures highlight financial challenges that rural hospitals face amid workforce shortages, rising costs, and leveling reimbursement.

Thyme Care welcomes its new senior vice president to lead initiatives in value-based oncology care.

This second installment on the threat of forever chemicals examines the impactful policies brought about during the Biden-Harris administration that are set to play a role in the future manufacturing, use, and monitoring of these harmful substances.

Aetna has become the first major US insurer to expand access to fertility services by covering intrauterine insemination as a medical benefit for all eligible plans, marking a significant move toward greater equity in family-building options for people of all backgrounds.

Medicare has not clearly defined what constitutes "established cardiovascular disease," leading to variability in potential patient eligibility; therefore, researchers aimed to estimate the number of Medicare beneficiaries who would become newly eligible for semaglutide under different definitions.

New research reveals the first documentation of a significant rise in heat-related mortality rates in the US through 2023, contrasting with earlier studies that indicated a declining trend.

Learn more about the negotiated Medicare drug prices and what the FDA's rejection of therapeutic MDMA means for mental health care through expert reactions. Other highlights include pharmacy-based HIV care, gaps in care for gastrointestinal stromal tumors, and the obesity epidemic.

Disparities in hypertension brought on by neighborhood deprivation were most prominently found in Black patients.

The researchers found inferior outcomes and higher accrued costs associated with alloimmunization in patients with myelodysplastic syndromes (MDS), a disease that relies on transfusion of red blood cells.

Spotty vaccine supplies have consumers searching for protection as the FDA prepares to approve updated COVID-19 shots.

The birth rate in the US continues its 17-year decline, with fertility levels now at their lowest in decades, according to CDC data.

The majority of federal savings indicated by the Inflation Reduction Act's Drug Price Negotiation Program can be attributed to 3 drugs.

Changes in formulary coverage for 2024 are impacting Medicare patients' access to and ability to afford various prescription medications.

Adverse outcomes in the aftermath of the COVID-19 pandemic continue to be evaluated as they pertain to social determinants of health, with these authors investigating improvements in food hardship among families participating in the Supplemental Nutrition Assistance Program (SNAP).

Some groups praised CMS after it announced the 10 negotiated Medicare drug prices while others criticized its potential impacts on drug competition and development.

Health plans can improve their Medicare Advantage Star Ratings by focusing on member relationships, ensuring proper documentation, grouping measures, staying updated with regulatory changes, and optimizing their strategy based on numerical targets.

This article first appeared on The Center for Biosimilars®.

CMS today announced the agreed-upon lower prices for all 10 drugs selected for price negotiations under the Inflation Reduction Act.

On this episode of Managed Care Cast, we discuss strategies to improve 2025 Medicare Advantage Star ratings, especially for smaller plans, with Marge Ciancetta, the product manager of Cotiviti's Star Intelligence solution.

Health insurance premiums for 2025 are expected to rise slightly due to higher prescription drug costs and inflation, according to a new analysis from the American Academy of Actuaries.

As the 2024 election approaches, older adults, who comprise more than half of ballots cast, are highly concerned about health care costs, financial scams, and fraud. Concern varies based on gender and political ideology.

This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA’s accelerated approval program for oncology drugs came to different conclusions.